Epilepsy: cannabis research overview
Decisions depend on the exact diagnosis, previous seizure treatments and accompanying medicines. A seizure diary can help make changes easier to assess. Agree with the team which seizure types and everyday consequences will be monitored. A standardised medicine cannot be equated with a retail CBD oil.
Research profile, not a treatment recommendation
Evidence
Swissmedic documents the initial 2021 authorisation and the 2022 extension for tuberous sclerosis complex. Current prescribing information remains decisive. Whether clobazam or another medicine belongs in the accompanying treatment must be assessed individually; this page does not claim a universal clobazam requirement. Authorisation and individual treatment response are separate questions. For each study, check who participated, what was compared and whether the measured difference matters in everyday life.
Mechanism of action
A mechanism described in a laboratory is not evidence of benefit in humans. Clinical outcomes for the specific condition and medicine matter. Receptor or terpene models do not predict individual treatment success.
Understanding cannabinoid and terpene profiles
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Individual dosing and monitoring
This reference provides no starting dose or escalation schedule. If treatment is considered, the preparation, dose, adjustments and monitoring must be individualised. Different products are not directly interchangeable; drops and sprays are not universal dose units.
Routes of administration
The route of administration is part of choosing a specific medicine. Results for one standardised preparation do not automatically establish the effects of another form. Discuss changes with the treating clinician.
Side effects
Prescribing information includes liver risks and interactions, particularly with certain antiseizure medicines. Monitoring must fit the preparation and accompanying treatment. This article provides no dosing schedule for children or adults. Do not independently replace antiseizure treatment with CBD; follow the individual emergency plan for acute seizures.
Interactions & cautions
Have the complete medication list checked, including non-prescription products. CBD can also cause interactions. Pregnancy, breastfeeding, liver disease and previous mental health difficulties may matter; the specific medicine’s prescribing information is decisive.
Prescription & insurance (Switzerland)
Since August 2022, medical prescribing of cannabis medicines no longer requires an exceptional FOPH permit. This does not establish authorisation for every condition or automatic reimbursement. The preparation, indication and applicable reimbursement rules need separate assessment.
Driving fitness
If a person can demonstrate that THC comes from medication prescribed by a doctor, its presence alone does not establish unfitness to drive (Article 2(2ter) of the Swiss Traffic Rules Ordinance). Actual driving ability remains decisive. A prescription is therefore not blanket permission to drive. Discuss possible effects on attention and reactions with your treating clinician. Do not drive while impaired, and take particular care when starting or changing treatment. Safety-sensitive tasks at work also need an individual assessment.
FAQ
What can be said about effectiveness?
Epidyolex is an authorised CBD medicine for certain epilepsy syndromes, not a general approval of CBD for every form of epilepsy. Swiss indications include defined adjunctive treatments for Lennox–Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. Eligibility and accompanying medicines differ, and treatment requires specialist care.
Does a prescription guarantee reimbursement?
No. Prescribing, medicine authorisation and reimbursement are separate questions. Clarify which rules apply to the preparation and indication, including whether prior reimbursement approval is needed.
Is there a universally recommended product profile?
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Does a prescription automatically allow driving?
A prescription alone cannot answer that question. Where medically prescribed use is demonstrated, detecting THC does not by itself establish unfitness to drive. Driving while impaired remains prohibited. Discuss your individual circumstances with your treating clinician.